Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
Pre-existing hypertension and age ≥60 years are significant clinical risk factors for bevacizumab-related hypertension in mCRC patients. Bevacizumab-related hypertension did not affect overall survival. Clinicians should closely monitor BP within the first 2 months of bevacizumab treatment in high-risk patients.
Authors
- Zhuoling Zheng (ORCID: https://orcid.org/0000-0003-3506-5261)
- Yiting Wang
- Jingwen Xie (ORCID: https://orcid.org/0000-0002-5594-8283)
- Min Gao (ORCID: https://orcid.org/0000-0003-2424-1573)
- Yihong Zhao (ORCID: https://orcid.org/0000-0001-8730-0476)
- Xiaoyan Li (ORCID: https://orcid.org/0000-0002-3292-019X)
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.3389/fphar.2024.1463026
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Sun Yat-sen University
- Natural Science Foundation of Guangdong Province